[go: up one dir, main page]

SG11202003912RA - Single Domain Antibodies that Bind to CD137 - Google Patents

Single Domain Antibodies that Bind to CD137

Info

Publication number
SG11202003912RA
SG11202003912RA SG11202003912RA SG11202003912RA SG11202003912RA SG 11202003912R A SG11202003912R A SG 11202003912RA SG 11202003912R A SG11202003912R A SG 11202003912RA SG 11202003912R A SG11202003912R A SG 11202003912RA SG 11202003912R A SG11202003912R A SG 11202003912RA
Authority
SG
Singapore
Prior art keywords
bind
single domain
domain antibodies
antibodies
domain
Prior art date
Application number
SG11202003912RA
Inventor
Verena Brucklacher-Waldert
Carolyn Edwards
James Legg
Jayesh Majithiya
Brian Mcguinness
Christine Rossant
Yumin Teng
Original Assignee
Crescendo Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1718734.5A external-priority patent/GB201718734D0/en
Priority claimed from GBGB1718735.2A external-priority patent/GB201718735D0/en
Priority claimed from GBGB1808589.4A external-priority patent/GB201808589D0/en
Application filed by Crescendo Biologics Ltd filed Critical Crescendo Biologics Ltd
Publication of SG11202003912RA publication Critical patent/SG11202003912RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202003912RA 2017-11-13 2018-11-13 Single Domain Antibodies that Bind to CD137 SG11202003912RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1718734.5A GB201718734D0 (en) 2017-11-13 2017-11-13 Single domain antibodies that bind to CD137
GBGB1718735.2A GB201718735D0 (en) 2017-11-13 2017-11-13 Bispecific molecules that bind to CD137 and PSMA
GBGB1808589.4A GB201808589D0 (en) 2018-05-24 2018-05-24 Single domain antibodies that bind CD137
PCT/GB2018/053279 WO2019092451A1 (en) 2017-11-13 2018-11-13 Single Domain Antibodies that Bind to CD137

Publications (1)

Publication Number Publication Date
SG11202003912RA true SG11202003912RA (en) 2020-05-28

Family

ID=64457031

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202003978UA SG11202003978UA (en) 2017-11-13 2018-11-13 Molecules that bind to cd137 and psma
SG11202003912RA SG11202003912RA (en) 2017-11-13 2018-11-13 Single Domain Antibodies that Bind to CD137

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11202003978UA SG11202003978UA (en) 2017-11-13 2018-11-13 Molecules that bind to cd137 and psma

Country Status (10)

Country Link
US (2) US12077595B2 (en)
EP (2) EP3710477A1 (en)
JP (3) JP7312168B2 (en)
KR (2) KR20200080304A (en)
CN (4) CN118955716A (en)
AU (2) AU2018363292A1 (en)
CA (2) CA3082297A1 (en)
IL (2) IL274371A (en)
SG (2) SG11202003978UA (en)
WO (2) WO2019092452A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7190901B2 (en) 2016-01-12 2022-12-16 クレッシェンド、バイオロジックス、リミテッド Molecules that bind prostate specific membrane antigen (PSMA)
GB201607968D0 (en) 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
EP3565842A1 (en) 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
CN118955716A (en) 2017-11-13 2024-11-15 克雷森多生物制剂有限公司 Single domain antibodies that bind CD137
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
JP2020132572A (en) * 2019-02-20 2020-08-31 旭化成株式会社 Silanol composition, cured product, and production method
EP3969474A1 (en) * 2019-05-15 2022-03-23 Crescendo Biologics Limited Binding molecules
BR112021008870A2 (en) * 2019-08-12 2021-11-30 Abl Bio Inc Antibody, one or more polynucleotides, composition, use of the antibody, and method of treating cancer.
AU2020381735B2 (en) * 2019-11-13 2024-07-25 Hefei Hankemab Biotechnology Co., Ltd Molecule capable of binding to human 4-1BB, and application of molecule
CR20220221A (en) * 2019-11-18 2022-07-11 Janssen Biotech Inc Anti-cd79 chimeric antigen receptors, car-t cells and uses thereof
AU2021301927B2 (en) * 2020-06-30 2025-07-31 Nona Biosciences (Suzhou) Co., Ltd. 4-1BB binding protein and application thereof
CA3194771A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
CN114195894B (en) * 2020-09-17 2025-02-25 普米斯生物技术(珠海)有限公司 An antibody targeting 4-1BB and its application
TW202306984A (en) * 2021-05-21 2023-02-16 英屬開曼群島商百濟神州有限公司 Anti-cd137 antibodies and methods of use
WO2022242682A1 (en) * 2021-05-21 2022-11-24 Beigene, Ltd. Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
CN113621065B (en) * 2021-08-30 2023-08-01 武汉海沙百得生物技术有限公司 Fully human antibody targeting 4-1BB and its preparation method and application
CN118176211A (en) * 2021-08-31 2024-06-11 礼新医药科技(上海)有限公司 Anti-4-1BB Nanobody
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
JP2025531938A (en) * 2022-09-22 2025-09-25 アブリンク バイオテック カンパニー リミテッド Anti-4-1BB nanobodies, their production and uses
WO2024109678A1 (en) * 2022-11-21 2024-05-30 Beigene, Ltd. Anti-cd137 antibodies and methods of use
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
JP2025022410A (en) 2023-08-03 2025-02-14 ルネサスエレクトロニクス株式会社 Semiconductor device and its manufacturing method
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025214249A1 (en) * 2024-04-12 2025-10-16 Suzhou Biomissile Pharmaceuticals Co., Ltd. Anti-4-bb single domain antibodies, bispecific antibodies and uses thereof
CN118629502A (en) * 2024-06-19 2024-09-10 中山百灵生物技术股份有限公司 Nucleotide sequence experimental prediction and optimization system based on data processing

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP2360169B1 (en) 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
JP5139800B2 (en) * 2004-06-03 2013-02-06 ノビミューン エスアー Anti-CD3 antibody and method of use thereof
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
PL1851250T3 (en) 2005-02-18 2012-10-31 Squibb & Sons Llc Human monoclonal antibody to prostate specific membrane antigen (psma)
AU2006341615A1 (en) 2005-08-03 2007-10-18 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
AU2009225747A1 (en) 2008-03-17 2009-09-24 Allergan, Inc. S1P3 receptor inhibitors for treating inflammation
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
AU2009270793A1 (en) * 2008-07-18 2010-01-21 Oragenics, Inc. Compositions for the detection and treatment of colorectal cancer
CN102264762B (en) 2008-09-26 2018-03-27 达纳-法伯癌症研究公司 Human anti-PD-1, PD-L1 and PD-L2 antibodies and uses thereof
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US20130266567A1 (en) 2010-12-01 2013-10-10 Haren Arulanantham Anti-serum albumin binding single variable domains
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CN104159909A (en) 2012-02-22 2014-11-19 宾夕法尼亚大学董事会 Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
EP2847229B1 (en) 2012-05-07 2022-09-07 Elasmogen Limited Single domain binding molecule
AU2013265665B2 (en) * 2012-05-24 2017-10-26 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
CN103087171B (en) 2012-12-24 2015-01-14 中国人民解放军第四军医大学 anti-PSMA/FITC bispecific antibody for early diagnosis and treatment of prostate cancer and preparation method thereof
WO2014141192A1 (en) * 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
CN103333249A (en) 2013-06-14 2013-10-02 广州康合生物科技有限公司 PSMA (Prostate Specific Membrane Antigen) monoclonal antibody and applications thereof
WO2015034820A1 (en) 2013-09-04 2015-03-12 Bristol-Myers Squibb Company Compounds useful as immunomodulators
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
KR20150089702A (en) 2014-01-28 2015-08-05 제일모직주식회사 Novel compound, novel polymer, colorant including the same, positive photosensitive resin composition including the same, and color filter
KR20160106762A (en) 2014-01-28 2016-09-12 브리스톨-마이어스 스큅 컴퍼니 Anti-lag-3 antibodies to treat hematological malignancies
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
TWI754319B (en) 2014-03-19 2022-02-01 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
TWI726842B (en) * 2014-04-07 2021-05-11 日商中外製藥股份有限公司 Immune activation antigen binding molecule
DK3134438T3 (en) 2014-04-25 2020-12-07 Pf Medicament IGF-1R antibody and its use as an addressing vehicle in the treatment of cancer
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
TWI693232B (en) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
WO2016020856A2 (en) 2014-08-05 2016-02-11 MabQuest SA Immunological reagents
JP6919118B2 (en) 2014-08-14 2021-08-18 ノバルティス アーゲー Treatment of cancer with GFRα-4 chimeric antigen receptor
KR20170073647A (en) 2014-10-22 2017-06-28 크레센도 바이오로직스 리미티드 Transgenic mice
EP3215852A4 (en) 2014-11-05 2018-04-04 The Regents of the University of California Methods for stratifying non-responders to therapies that block pd1/pdl1 axis
ES2881484T3 (en) 2014-12-22 2021-11-29 Pd 1 Acquisition Group Llc Anti-PD-1 antibodies
BR112017020434A2 (en) * 2015-05-04 2018-06-26 Pieris Pharmaceuticals Gmbh fusion polypeptides, nucleic acid molecule, host cell, method for producing a fusion polypeptide, uses of fusion polypeptide, methods for activating signaling pathways, for costimulating cells, for inducing t lymphocyte proliferation, for directing assembly cd137, to induce a local t-cell response, to induce a local nk cell response, and to induce il-2 production
DK3298030T5 (en) * 2015-05-18 2024-10-07 Pieris Pharmaceuticals Gmbh Anti-cancerfusionspolypeptid
CN105061597B (en) 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 The monoclonal antibody of a kind of anti-PD-1 and preparation method thereof
GEAP202215554A (en) 2015-07-30 2022-06-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
CN106397592A (en) 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 Single-domain antibody directed at programmed death ligand (PD-L1) and derived protein thereof
CN105384825B (en) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
RU2018116402A (en) * 2015-10-07 2019-11-07 Ф. Хоффманн-Ля Рош Аг BESPECIFIC ANTIBODIES FOUR PRINCIPLES REGARDING THE COSTIMULATORY TNF RECEPTOR
IL300122A (en) 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc PD1 and/or LAG3 Binders
IL304871A (en) * 2016-01-11 2023-10-01 Inhibrx Inc Multivalent and multispecific 41bb-binding fusion proteins, compositions comprising same and uses thereof
JP7190901B2 (en) 2016-01-12 2022-12-16 クレッシェンド、バイオロジックス、リミテッド Molecules that bind prostate specific membrane antigen (PSMA)
CN105968203A (en) 2016-02-03 2016-09-28 南昌大学 Single-domain heavy chain antibody for anti-prostate specific membrane antigen extracellular region
CN105968205B (en) 2016-02-03 2019-04-26 中国人民解放军第三军医大学第三附属医院 A Nanobody Against Prostate Specific Membrane Antigen
CN105968204B (en) 2016-02-03 2020-01-21 中国人民解放军第三军医大学第一附属医院 Single-domain heavy chain antibody for resisting prostate specific membrane antigen
KR102426765B1 (en) 2016-04-22 2022-07-29 엘리게이터 바이오사이언스 에이비 Novel bispecific polypeptide for CD137
GB201607968D0 (en) 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
KR102530742B1 (en) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. single domain serum albumin binding protein
TW201806972A (en) 2016-05-27 2018-03-01 美商艾伯維生物醫療股份有限公司 Bispecific binding proteins
RU2022101604A (en) 2016-12-07 2022-03-29 Аблинкс Нв IMPROVED SINGLE IMMUNOGLOBULIN VARIABLE DOMAIN BINDING TO SERUM ALBUMIN
CN107674122A (en) 2016-12-28 2018-02-09 天津天锐生物科技有限公司 A kind of single domain antibody for identifying human serum albumins
EP3565842A1 (en) 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
WO2018148223A1 (en) 2017-02-09 2018-08-16 Memorial Sloan Kettering Cancer Center Anti-kir3dl1 antibodies
WO2018224439A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
EP3425763B1 (en) 2017-07-03 2020-11-18 France Brevets Coupling interface and method of operation
BR112020000228A2 (en) 2017-07-06 2020-07-14 Merus N.V. antibodies that modulate a biological activity expressed per cell
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
US12202911B2 (en) * 2017-10-10 2025-01-21 Numab Therapeutics AG Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
CN118955716A (en) * 2017-11-13 2024-11-15 克雷森多生物制剂有限公司 Single domain antibodies that bind CD137
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
GB201818460D0 (en) 2018-11-13 2018-12-26 Crescendo Biologics Ltd Single domain antibodies that bind human serum albumin
EP3969474A1 (en) 2019-05-15 2022-03-23 Crescendo Biologics Limited Binding molecules

Also Published As

Publication number Publication date
CA3082321A1 (en) 2019-05-16
JP2023126951A (en) 2023-09-12
EP3710477A1 (en) 2020-09-23
CN111699197B (en) 2024-08-23
US20200362047A1 (en) 2020-11-19
CA3082297A1 (en) 2019-05-16
WO2019092451A1 (en) 2019-05-16
EP3710478A1 (en) 2020-09-23
JP2021502104A (en) 2021-01-28
KR20200080304A (en) 2020-07-06
AU2018363291A1 (en) 2020-05-21
US20200362051A1 (en) 2020-11-19
SG11202003978UA (en) 2020-05-28
KR20200083574A (en) 2020-07-08
CN111683968A (en) 2020-09-18
WO2019092452A1 (en) 2019-05-16
AU2018363292A1 (en) 2020-05-21
CN111683968B (en) 2024-07-05
CN118667027A (en) 2024-09-20
JP7312168B2 (en) 2023-07-20
IL274371A (en) 2020-06-30
JP2021502810A (en) 2021-02-04
CN111699197A (en) 2020-09-22
US12077595B2 (en) 2024-09-03
IL274370A (en) 2020-06-30
CN118955716A (en) 2024-11-15

Similar Documents

Publication Publication Date Title
IL274370A (en) Single domain antibodies that bind to cd137
IL284336B (en) Antibody therapeutics that bind ctla4
IL276537A (en) Antibodies binding to gprc5d
IL275268A (en) Antibodies to lilrb2
IL254088A0 (en) Antibody therapeutics that bind cd137
IL261188A (en) Antibodies to tigit
ZA201801427B (en) Antibodies that specifically bind to tl1a
IL256848A (en) Antibody molecules which bind cd45
IL256846A (en) Antibody molecules which bind cd22
IL254260A0 (en) Antibody therapeutics that bind tim3
EP3325009A4 (en) Antibody therapeutics that bind lag3
EP3247407A4 (en) Non-immunogenic single domain antibodies
IL269394A (en) Antibodies binding to steap-1
IL275498A (en) Heavy chain antibodies binding to cd22
ZA201907065B (en) Monoclonal antibody to pd-l1
IL271128A (en) Novel anti-cd3 antibodies
IL273235A (en) Heavy chain antibodies binding to ectoenzymes
EP3131580A4 (en) Antibody therapeutics that bind cd147
ZA202002044B (en) Monoclonal antibody to il-5rα
GB201609742D0 (en) Improvements relating to antibodies
IL272015A (en) Antibodies to MADCAM
EP3297663A4 (en) Antibodies that bind to axl proteins
SG10202010600SA (en) T cell receptor like antibodies that bind to p53-mhc class i complex
GB201718734D0 (en) Single domain antibodies that bind to CD137
HK40038439A (en) Single domain antibodies that bind to cd137